- Info
- Insider Trading
- Financials
- Holders: INDV, INDV
Income Tax Expense (Benefit) of Indivior Pharmaceuticals, Inc. from 31 Dec 2022 to 31 Dec 2025
- Taxonomy & unit
- us-gaap: USD
- Description
- Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
- Summary
-
Indivior Pharmaceuticals, Inc. quarterly and annual Income Tax Expense (Benefit) in USD history and change rate from 31 Dec 2022 to 31 Dec 2025.
- Indivior Pharmaceuticals, Inc. Income Tax Expense (Benefit) for the quarter ending 31 Dec 2025 was $21,000,000, a 224% decline year-over-year.
- Indivior Pharmaceuticals, Inc. Income Tax Expense (Benefit) for the twelve months ending 31 Dec 2025 was $29,000,000, a 123% increase year-over-year.
- Indivior Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2025 was $29,000,000, a 123% increase from 2024.
- Indivior Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2024 was $13,000,000.
- Indivior Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2023 was $19,000,000, a 56% increase from 2022.
- Source SEC data
- View on sec.gov
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Change (%)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Change (%)
Indivior Pharmaceuticals, Inc. Quarterly Income Tax Expense (Benefit) (USD)
| Period | TTM Value | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|---|
| Q4 2025 | $29,000,000 | $21,000,000 | -$38,000,000 | -224% | 01 Oct 2025 | 31 Dec 2025 | 10-K | 26 Feb 2026 | 2025 | FY |
| Q3 2025 | $67,000,000 | $5,000,000 | -$13,000,000 | -162% | 01 Jul 2025 | 30 Sep 2025 | 10-Q | 30 Oct 2025 | 2025 | Q3 |
| Q2 2025 | $80,000,000 | $44,000,000 | +$67,000,000 | 01 Apr 2025 | 30 Jun 2025 | 10-Q | 31 Jul 2025 | 2025 | Q2 | |
| Q1 2025 | $13,000,000 | $11,000,000 | $0 | 0% | 01 Jan 2025 | 31 Mar 2025 | 10-Q | 01 May 2025 | 2025 | Q1 |
| Q4 2024 | $13,000,000 | $17,000,000 | 01 Oct 2024 | 31 Dec 2024 | 10-K | 26 Feb 2026 | 2025 | FY | ||
| Q3 2024 | $8,000,000 | 01 Jul 2024 | 30 Sep 2024 | 10-K | 26 Feb 2026 | 2025 | FY | |||
| Q2 2024 | $23,000,000 | 01 Apr 2024 | 30 Jun 2024 | 10-K | 26 Feb 2026 | 2025 | FY | |||
| Q1 2024 | $11,000,000 | 01 Jan 2024 | 31 Mar 2024 | 10-K | 26 Feb 2026 | 2025 | FY |
Indivior Pharmaceuticals, Inc. Annual Income Tax Expense (Benefit) (USD)
| Period | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $29,000,000 | +$16,000,000 | +123% | 01 Jan 2025 | 31 Dec 2025 | 10-K | 26 Feb 2026 | 2025 | FY |
| 2024 | $13,000,000 | +$32,000,000 | 01 Jan 2024 | 31 Dec 2024 | 10-K | 26 Feb 2026 | 2025 | FY | |
| 2023 | $19,000,000 | +$24,000,000 | +56% | 01 Jan 2023 | 31 Dec 2023 | 10-K | 26 Feb 2026 | 2025 | FY |
| 2022 | $43,000,000 | 01 Jan 2022 | 31 Dec 2022 | 10-Q | 30 Oct 2025 | 2025 | Q3 |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.